Americas

Abbott Laboratories Biotech Facility
Barceloneta, where the new Abbot Laboratories facility is based, is on the northern coast of the island of Puerto Rico.	Humira has now been approved for the treatment of psoriasis in Europe.	Humira is a CAT-derived human anti-tumour necrosis factor alpha which mediates inflammation.
Puerto Rico is a Caribbean island which is effectively a protectorate of the US. The island offers significant tax advantages and incentives to companies locating facilities there.	The diagrammatic structure of Humira, Abbott Laboratories' successful biological compound.

ABC Laboratories, Pharmaceutical Facility,
The new ABC facility is situated just southwest of Columbia.	The lab space has been outfitted and as of June 2008 is being occupied.	There is a central services arrangement at the new ABC facility.
The facility has 20ft-high ceilings and as much natural light as possible is being channelled into the building.	The new building has 30,000ft² of office and 60,000ft² of laboratory space.

Accucaps Industries, Manufacturing Capacity, Ontario
The Strathroy facility in Ontario began a project in April 2008 to double production capacity.	Accucaps is one of the largest soft gel cap manufacturers in North America.	The Accucaps facility in Strathroy has been converted to focus on health and nutritional products.
The company's strategy is based on stronger legislation for food and health products from the Canadian Government.

Achillion Pharmaceuticals Biotech Facility,
New Haven County is seeing an increasing number of biotechnology investments which should play a vital role in revitalising the local economy.	The opening ceremony of the New Haven Biotech facility was held in December 2000.	Zinc finger proteins are essential to the Achillion Pharmaceuticals growth strategy.
Zinc finger proteins allow proteins to recognize nucleic acids (DNA or RNA) and thus modulate genes that the nucleic acids encode. The diagram shows carbon tube tracings, which illustrate the distinct 3-dimension structures of various representative human zinc finger 'CCCC', and 'CCHH' motifs, versus the retroviral 'CCHC' motif.

Amgen Helix Project
The Helix project is a $750m research and development facility in Seattle.	The first phase of construction was completed in 2004.	The Helix construction includes a bridge over the railway, which is open to the public.

Amgen Pharmaceutical Manufacturing Facility,
Immunex decided to purchase an existing manufacturing facility in West Greenwich, and retrofit it to produce the Enbrel drug.	Work on the BioNext project in West Greenwich began in November 2001.	Part of the utilities infrastructure at the new BioNext mammalian protein manufacturing facility.
Immunex has also recently invested in a pharmaceutical facility in Bothell in Washington.	Part of an interim Enbrel manufacturing site at West Greenwich owned by Wyeth-Ayerst Pharmaceuticals and using Immunex's process technology.	The plant is now fully operational.
The water treatment plant will use 800,000 gallons per day.

Amgen Process Development Facility,
The Immunex facility at Bothell needed specially constructed water pipe systems for the supply of its exceptionally pure water. These had to be made with specialised machines.	The process development facility at Bothell was the third major facility to be built there.	The process development facility at Bothell was in use by the end of 2001.
The Bothell facility covers 50,000ft².	The Bothell process development facility saw production gradually geared up during the course of 2001 to full capacity by the opening of 2002.	As well as the Bothell facility, Immunex is also investing in facilities in Seattle (the Helix project).

Amylin Pharmaceuticals
Insulin secretion mechanism from the pancreas.	Amylin's exanetide suppresses glucagon secretion in the pancreas.	Byetta (exanetide) is injected twice a day. A long-acting version is also in development by Amylin.
Amylin is a peptide secreted from the pancreas beta cells which mediate in insulin secretion.	The biopharma manufacturing facility is set to be complete in late 2008.	Amylin has received over $117m in benefits and assistance for locating its manufacturing facility in Ohio.

AstraZeneca Bulk Pharmaceutical
AstraZeneca's facility in Guayama, Puerto Rico.	PRIDCO hopes that Zeneca's investments will enhance the island’s reputation as a manufacturing centre.	According to the company's own figures, its soluble, oral version of Zomig was widely welcomed by the sample group. If this is the case, it should boost demand.

Baxter BioPharma Solutions Parenteral
The Bloomington plant manufactures pre-filled syringes, vials and cartridges for the packaging of vaccines and drugs.	The pre-filled syringe production facility consists of 24 modules that include formulation, preparation and supporting utility rooms.	Research and development in formulation.
Production equipment area.	Skid/module being fabricated.	High-speed syringe filling line.
Module being put in place on prepared foundations at the Phase IV extension.	Completed prep room at the new extension.	Separate services area.

Baxter International Cartago Facility
The Baxter Cartago plant is the first outside the US to receive ISO certification.	The plant at Cartago, Costa Rica, focuses on products for medication delivery, including sets for IV administration.	Baxter is meeting targets such as reduced product defect levels and lower energy consumption at its Cartago plant.

Bayer Corporation Biotechnology Plant
Bayer Manufacturing's multipurpose biotechnology plant in Berkeley, California, USA.	US spending on health is predicted to rise steadily in line with rising GDP.	The plant is a cGMP-FDA validated facility, and is the first in North America to meet one of the most rigorous international environmental standards in the world, the ISO 14001 standard.
Kogenate FS produced by Bayer at Berkley is one of the best selling factor VIII products for the treatment of haemophilia.

Bayer Healthcare Pharmaceuticals Plant, Snohomish County, Washington State
The Northpointe Corporate Center has a range of occupants from pharmaceutical companies to semiconductor manufacturers.	The administration block in a state of construction.	Construction at the Northpointe Corporate Center well underway by Skanska USA.
Bayer Healthcare produces a range of other drugs for the North American market including the contraceptive pill.	The inflammatory process brought on by Crohn’s disease, which can be relieved by the use of Leukine. The drug was tested for this use in Phase III trials but results were found to be insufficient.

Biolex Therapeutics Facility Expansion, Pittsboro, North Carolina
Lemna being grown on a small scale for development.	The new Biolex Hepatitis treatment Locteron in development.	The plant growth room in the new facility.
The Biolex facility in Pittsboro.	The Lemna (Duckweed) plant in its natural environment.

Biopol Allergy Immunotherapy Manufacturing Facility, Idaho
The new Biopol plant from a front elevation. The facility is expected to create approximately 50 jobs when completed in 2009.	A plan view of the new Biopol plant. It will be the largest production site of raw materials for the company's products.	Grass pollen is a big problem for allergy sufferers.
Pollen particles make excellent allergens, causing a lot of suffering for many people during the summer months.	Gravax is a new sublingual treatment for hay fever sufferers that is conveniently administered as a fast-dissolving tablet

Biosite HQ and Manufacturing Campus, Mera Misa, California
Cardiac profiler testing apparatus used to examine blood from cardiac patients and aid diagnosis.	One of the R&D laboratories.	Part of the new headquarters and campus buildings.
The triage parasite panel is an enzyme immunoassay used for the detection of antigens and is used as an aid in the diagnosis of intestinal parasitic disease.	Biosite has broadened its BNP product line to include the triage BNP test for Beckman Coulter immunoassay systems.

Bristol Myers Squibb
The city of New Brunswick in the US is known as the healthcare capital because of the number of pharmaceutical companies based there, including BMS.	Taxol is just one drug which has been a great success story for BMS.	Development of specific drugs takes time and money. The new centre at New Brunswich should help to make the process more rapid and more efficient.
The ODS areas at the BMS plant all have high containment and isolator technology.	BMS recently won the Facility of the Year 2008 award for equipment innovation at the New Brunswick plant.

Bristol Myers Squibb Manufacturing Plant,
The new Bristol Myers Squibb plant is situated in Devens, 35 miles northwest of Boston, Massachusetts,US.	The facility will have six 20,000l reactors for the manufacture of multiple biotech products.	The state of Massachusetts passed new legislation to offer greater incentives for the BMS plant to be located in Devens, allowing the company to claim a refund for 5% of its investment.
The new Bristol Myers Squibb facility has a $600,000 wastewater pre-treatment plant, designed to handle a flow capacity of 530,000gal per day.	The BMS facility is being built on a business park developed on the site of Fort Devens, which closed in 1996. The site was purchased by MassDevelopment.

Bristol-Myers Squibb,
Orencia is a new treatment for rheumatoid arthritis and will now be produced at the Manatí plant.	BMS has invested $220m in the Manatí plant and there is further expansion on the cards.	Orencia is produced in a solid dosage form.
Manati is in the north of Puerto Rico and is due to become a major centre for biologics production for BMS.	The damage caused by the inflammatory process set up by rheumatoid arthritis; Orencia controls inflammatory responses.

Cambridge Major Laboratories Active Pharmaceutical
Construction of the first floor of the new API production facility.	[top] back view of the facility [middle] area where pilot plants will be installed [bottom] area where 500 gallon reaction vessel will be installed.	Images showing building work with emphasis on roof construction.
[top] shipping and receiving area [bottom] billboard of site showing illustration of completed facility.	A view showing reactors in the Oread pilot plant purchased by Cambridge Major in 2002.

Cedarburg Pharmaceuticals Intermediate and API
Cedarburg Pharmaceuticals, LLC are making a number of investments in the facility.	Emerson Process Management was given the lead contract for automation at the Grafton pharmaceutical plant.	Cedarburg Pharmaceuticals' facility in Grafton, Winsconsin, USA.
A graph showing health expenditure as a percentage of GDP.

Chao Center for Industrial Pharmacy and Contract
The Allen Chao Centre for Industrial Pharmacy and Contract Manufacturing was coordinated and designed by Purdue Architects and Lockwood Greene / CH2MHill.	A map of the Purdue Research Park - the Chao Centre facility is one of only five university-affiliated pharmaceutical manufacturing centres in the United States.	The changing room for staff to use prior to entering high-grade cleanroom - the cGMP areas are required to be completely secure, operate under differential air pressure and be manned by highly trained individuals.
The first drugs to come off the production line are expected to be antibiotics that are effective for treating Multiple-Drug Resistant Tuberculosis (MDR-TB).	The cGMP compliant facility will assist with the development and production of legacy drugs, which are drugs for diseases and conditions that affect the underprivileged, especially in third-world countries.	Five multi-use rooms are part of the 10,000ft² of good manufacturing process space at the Chao Centre for Industrial Pharmacy and Contract Manufacturing.
A microscopic view of TB bacillus in sputum (stained red).

ChemSyn (Aptuit) Pharmaceutical Manufacturing Plant,
The exterior of the expanded Harrisonville pharmaceutical manufacturing facility.	The main reactor room at Harrisonville.	The isolation suite at the Harrisonville plant.
The drying/packaging suites.	Isolation hoods at the facility.	The Schott Scrubber system.

Cook Pharmica Biotechnology Plant
The old Thomson plant from the air.	The new Cook Pharmica campus.	Chromatography equipment installed at the biotechnology plant.
QA labs at the Cook Pharmica Biotechnology plant.	Buffer and media preparation and storage.

CoreRX Tampa Facility Expansion, Florida
Architect's sketch of the expansion of the CoreRx Tampa facility.	The Tampa site expansion will add 7,500ft of laboratories.	The expansion will include a number of new suites, laboratories and meeting rooms.
The Tampa site will also be made the headquarters of CoreRx when the expansion is complete.	ACI BOLAND is assisting ARCO Design Build in planning and architecture of the Tampa facility.

Cortex Biotech Facility, Missouri
The new CORTEX ONE building as an artist's rendering.	A map to show the extent of CORTEX property in St. Louis for development.	The CORTEX ONE building completed.
CORTEX ONE during construction.	The campus will provide space for biotech companies to develop.

Dendreon Biopharmaceutical Manufacturing Plant, Seattle
Prostate cancer is the third most prevalent cancer worldwide.	A micrograph of prostate cancer. Provenge is expected to help treat the often-fatal disease.	The Dendreon plant has scaled back its clean rooms from 48 to 12.
The New Jersey site is on the other side of the US from Dendreon's Headquarters in Seattle.	Provenge is expected to be approved by the FDA soon, as additional evidence from clinical trials has been produced.

DSM Biologics Biopharmaceutical Manufacturing
DSM Biologics laboratory technician monitoring media preparation.	PER.C6 cell line for production of recombinant proteins.	A view of the top of a bioreactor skid.
DSM technical staff working in clean room facilities.	A tumbler for use in the production process.	The vitamin premix plant in Mexico is state-of-the-art.
DSM is currently considering new investment, but this may be hampered by increased prices of raw materials used for vitamins.	Vitamin products being packaged; the most sophisticated new technologies were used for production.	The plant also produces vitamins in traditional forms for the Latin American market.

DSM Premix Vitamin Plant,
Location of Roche´s El Salto vitamin premix plant.

Eastman Chemical Company
Eastman Chemical Company broke ground on its good manufacturing practice (cGMP) facility, the first of two US cGMP manufacturing facilities to be built at Eastman's Arkansas site, in 1999.	Eastman Chemical Company's new facility in Batesville, Arkansas, USA.	Graph showing relationship between spending on health and GDP.

Eli Lilly Biotech Pilot Plant, Indianapolis
The new K 360-362 building complex.	The support laboratories will form the nerve centre of Eli Lilly R&D.	Biotech equipment at the plant is state-of-the-art.
Even though the plant is pilot scale it is fully capable of producing commercial quantities of drug substance.	All equipment is fully automated and regulated.

Eli Lilly Biotechnology Centre,
Eli Lilly's San Diego biotechnology centre is located within a 450,000ft core and shell facility.	The Campus Pointe facility is environmentally friendly and set to become the first LEED-certified core and shell facility in California.	The centre has been developed as part of the company's strategy to manufacture more biotechnology drugs for the treatment of conditions such as diabetes.

Eli Lilly Humalog Manufacturing Facility, Carolina
Eli Lilly began production of the insulin product Humalog at its new bulk manufacturing facility in Carolina, Puerto Rico, in mid-2005.	Pro-insulin and human insulin, showing where the trypsin cleavage occurs.	Scanning electron micrograph of E. coli as used for recombinant DNA techniques.
Humalog pen used for dispensing the insulin by a non-injection technique.	Insulin crystals from the purification process.

Fiocruz
The new Fiocruz facility is part of an existing vaccine technological complex comprised of three main buildings: the bacterial vaccines production unit, the centre of final processing and the viral vaccine production unit (which was the last unit to be completed).	Water piping and compressed air services in the vaccine manufacturing centre.	Fiocruz Instituto de Tecnologia em Imunubiologicos' facility in Manguinhos near Rio de Janeiro, Brazil.

Genentech Cell Culture Plant No 2 Expansion
Herceptin will be one of the major products from Genentech's new CCP2 facility.	Vacaville is in northern California, about 58 miles from the Genentech HQ in San Francisco.	Xolair is Genentech's new product for the treatment of allergic asthma.
Sjorgens syndrome is an autoimmune condition which can be treated successfully with Rituxan, another drug to be made at the new CCP2 facility in Vacaville.	Genentech now has over 50 peptide and antibody products in its commercial pipeline.

Genentech Inc
Genentech is building the new fill and finish facility on a 75-acre site near Hillsboro in Oregon.	The new Genentech facility is expected to begin production toward the end of 2009 and will focus on products to treat cancer, arthritis and asthma, as well as those to promote tissue growth and repair.	Nutropin is a recombinant growth hormone marketed by Genentech and will be produced at the new Hillsboro plant.
The drug Herceptin is one of Genentech's success stories; the company is regarded as a pioneer in the biotech industry.	The State of Oregon has provided financial incentives for Genentech to relocate its fill and finish facility there.	Genentech has now been acquired by Swiss company Hoffman La Roche, which will run the Hillsboro plant.

Genentech Manufacturing Facility (NIMO)
The New Idec Manufacturing Operation (NIMO) at Oceanside, San Diego, was completed by Biogen Idec in 2005 and sold to Genentech later that year.	Fermentation vessels in the manufacturing hall.	Following FDA approval, Genentech will manufacture its colon cancer drug, Avastin, at Oceanside.
Avastin (white monoclonal antibody) acting upon cancerous cells.	The NIMO site, showing the manufacturing building partially completed in the foreground.	The plant is now ready to produce the new anticancer treatment Avastin.

Genzyme Manufacturing Expansion,
Cerezyme is one of Genzyme's bestselling drugs and the new expansion will enhance production.	In Fabry disease patient's Alpha galactosidase is a protein that is deficient but Genzyme produces Fabrazyme to combat the condition.	Genzyme produces a range of orphan drugs for less well-known medical conditions.
The new ALF expansion will give the Allston Landing facility more space for manufacturing support operations.	The Allston Landing facility first came on-line in 1996 and produces five different drugs.

Genzyme Science Center,
The facade of the new Genzyme Science Center has used a great deal of glass to make full use of natural light on the inside.	The Genzyme building has a Gold LEED certification, one of only ten in the US to do so.	The central core of the Genzyme Science Center was designed to foster collaboration and open plan freeform meetings.
Genzyme's lab space uses state-of-the-art equipment and methodology.	Office space at the new Science Center building is very light and airy.

GlaxoSmithKline Manufacturing and Packaging
Map showing the location of Zebulon.

ImClone Systems Biopharmaceutical Plant,
Imclone Systems Incorporated's biopharmaceutical manufacturing facility in Branchburg, New Jersey, was approved by the FDA in July 2002 to produce investigational quantities of Erbitux (IMC-C225).	The plant is being further expanded to become a multi-product facility, with three production suites, along with downstream facilities and a total of 110,000 litres of production capacity.	Facility expansion building under construction.
Erbitux is a monoclonal antibody that blocks a specific molecular target, the Epidermal Growth Factor receptor (EGFr).	An excised colorectal tumor.	ImClone has a portfolio of targeted biologic treatments designed to address a variety of cancers.
Graph showing the higher and lower percentages of EGFr in different tumor types.

KBI Biopharma, North Carolina Center For Biomanufacturing, Durham, North Carolina
The lab space at the facility has been easily converted from semiconductor production to biopharmaceuticals.	This is an aerial view of the plant purchased from Mitsubishi in 2001.	The facility has been converted to a manufacturing facility for KBI in three phases.
The main building at the Teer Technical Park.	The cleanroom facilities were already installed in the facility.

Keata Pharma Pharmaceutical Production
The new Keata Pharma plant will be situated in North Sydney, Nova Scotia and will produce and package small runs of generic pharmaceuticals in solid and liquid form.	The company is investing $12.5m in the construction and outfitting of the new facility.	The University College of Cape Breton have established a new Biotechnology and Pharmaceutical Technology Certificate program issued jointly by PharmEng and the Cape Breton University.
PharmEng and Keata Pharma have received financial assistance for setting up the new plant and establishing the new training course at the university.	Varieties of solid dosage forms will be manufactured at the new facility when it is completed and commissioned.

Lonza Biologics Plant Expansion,
Ariel view of existing plant and the new construction at Lonza Biologics, New Hampshire.	Cell line storage at Lonza Biologics, New Hampshire.	Existing Lonza facility at Portsmouth, New Hampshire.
A mid-sized bioreactor vessel of 5,000l capacity.	Eculizumab was approved by the US FDA in March 2007 and acts against complement component C5.

Masy Systems Biorepository,
The Masy Systems biorepository in Pepperell, Massachusetts.	Chambers at the Masy facility offer temperature-controlled storage.	ESI cascading chamber being demonstrated by John Masiello, executive vice-president and senior validation engineer at Masy Systems.
The –80°C chambers have been constructed with four cooling systems.	The Masy facility has a strong security system to ensure controlled storage of biotechnology products.

Medimmune, Biologics Manufacturing Facility
A rendering of the new MedImmune facility where treatments for infectious diseases and vaccines will be produced.	The new facility is the phase one expansion of the Frederick site and is set to become MedImmune's primary manufacturing site.	MedImmune's drug Synagis is used in infants to treat respiratory conditions.
Frederick is very centrally placed in Maryland, good for logistics; the company was offered significant financial incentives to build on this site.	Governor Robert L Ehrlich Jr announced the expansion in October 2005.

Merck Vaccine Plant, Durham, NC
Merck is constructing a new 272,000ft² vaccine production plant on a 262 acre site in Treyburn Corporate Park on the north side of Durham, North Carolina, USA.	The project is expected to provide high-profile work for several local contracting firms.	The buildings will consist of a cGMP warehouse, an energy centre and 700ft of connecting utility corridor / spine.
One of the vaccines produced at the plant will be used to treat chicken pox.	MMR vaccine produced by Merck at their other site in Pennsylvania.	Rubella virus.

Norwich Pharmaceuticals Facility,
A leading provider of contract manufacturing and packaging services, Norwich Pharmaceuticals has served the pharmaceutical industry for over a decade.	Maintained scrupulously, the 375,000ft² Norwich plant features a small-scale manufacturing facility and an intermediate potency suite.	The manufacturing facility handles the clinical trials and smaller volume needs, while the potency suite supports requirements of dry blending and intermediate-potency tablet products.

Novartis Vaccine Manufacturing Facility, North Carolina
An aerial photograph of the Holly Springs construction site .	The location of Holly Springs.	An electron micrograph of the flu virus.
Flu vaccines have previously been produced using eggs .	The additional capacity at the Novartis plant will cater for a flu pandemic.	The plant is expected to be validated by 2011–2012 and operational by 2013.
In 2009 the HHS BARDA awarded Novartis an eight-year contract to support the design, construction, validation and licensing of the Holly Springs facility.

Novavax Vaccine Plant,
The Novavax facility is a pilot-scale facility but will soon be able to produce commercial quantities of vaccines.	VLP technology is expected to revolutionise vaccine production.	A VLP plant can be set up for about a quarter of the cost of an egg-based facility in half the time.
A lot of equipment used in production is disposable, meaning much lower costs for cleaning equipment and labour.	VLP vaccines need much lower doses than traditional vaccines to be effective.	The VLP approach uses non-pathogenic insect cell cultures in production.

Patheon Manufacturing Facility Expansion, Toronto
The Toronto facility for Patheon is being expanded, supporting commercial production capabilities including dispensing and primary packaging.	The 10,000ft² expansion at the Patheon facility will be dedicated to the production of oral contraceptives.	The operations in Toronto produce a wide range of tablets and capsules for pharmaceutical use.
The 263,000ft² Toronto facility is an integrated manufacturing and packaging site.

PDL Bioharma Biotech Manufacturing
The manufacturing / operations area at PDL's new biotech manufacturing facility will have four bioreactors for the manufacture of the same or multiple products depending on requirements.	The new PDL biotech manufacturing facility may be used to produce humanized antibodies such as Synagis and Xolair.	Herceptin, a humanized antibody product.
Zenapax, a humanized antibody product that PDL markets in association with Roche.	Micrograph showing erythrocytes, basophil, eosinophil and diagrammatic antibodies, illustrating selectivity.	Micrograph of antibodies on a cell surface.

Pfizer Pharmaceutical Facility,
Health Expenditure as a percentage of GDP in the USA.	Map showing location of Skokie, Illinois, USA.	The Q Building at the opening of the park in 2005.
The lab space at the park is first rate.	The campus is set to become a major hub for bioscience in Illinois.	The old front entrance area of the ex Pfizer campus.
The building can provide over 1 million ft² of lab and research space.	The Q Building was constructed as environmentally considerate and efficient.

Pharmstar Pharmaceuticals Plant,
Aspirin is an extremely useful drug for pain relief and as an anti-inflammatory as well as prophylactic treatment against stroke and heart attack.	The manufacturing facility will initially cover 17,000ft² but there is 196,000ft² to expand into.	Aquaprin has been in development since 1993 but is now at the point of coming to market.
Aquaprin comes in several flavours and completely dissolves in water.	The prototype Instaprin device.

Roche Bulk Active Ingredient Manufacturing Facility, Florence, SC
Construction on the Roche Carolina plant began in 1995, with further expansion taking place in 2007.	The plant, based in Florence, South Carolina, has a lot of modern features including an architectural glass roof.	The campus has only taken up a fraction of the land and plenty of room remains for expansion.
Roche's Tamiflu has already had great success in the Asian market.	Tamiflu is being stock piled as a first line of defence against an H5N1 epidemic.

Roche Diagnostics PCR Diagnostic Kits
Roche Diagnostics has built a new facility in New Jersey for the manufacture of PCR diagnostic kits.	AmpliChip CYP450 chip.	PCR electrophoresis gel used in quality control.
Molecular model of DNA double helix.	Section of DNA showing backbone and base pairs.	PCR step 1: denaturation.
PCR step 2: annealing.	PCR step 3: extension.

Roxane Laboratories Oral Solid Dosage Facility
Roxane Laboratories has upgraded its pharmaceutical manufacturing plant in Columbus, Ohio, to make a new respiratory drug called Spiriva.	Chronic Obstructive Pulmonary Disease (COPD) is a debilitating respiratory condition which is the fourth leading cause of death in the US.	Spiriva is a new daily treatment for COPD.
The Boehringer Ingelheim Handihaler used to administer Spiriva.

Sanofi Pasteur Vaccine Production Plant, Swiftwater, Pennsylvania
Sanofi has led the way with the first human vaccine in the US against the H5N1 virus.	The H5N1 virus has caused a highly pathogenic strain of influenza.	Bird flu is becoming an increasing worry across the world and Sanofi-Pasteur is hoping to be able to produce a viable vaccine to protect world populations from any pandemic.
One of the products from the plant will be a vaccine for the protection of infants.	The Swiftwater campus is gearing up to be a major vaccine production centre in the US.	The new facility building at Swiftwater has had an investment of $150m.

Serologicals Corporation Biotech Production Plant,
The new Serologicals Corporation biotechnology production facility in Lawrence, Kansas, USA, was constructed to manufacture the company's new serum-free cell culture supplement, EX-CYTE, for use in the preparation of media for biopharmaceutical production.	The plant was designed to manufacture 100,000 litres of EX-CYTE per year from two processing suites.	EX-CYTE is a growth enhancement media supplement manufactured from bovine serum.
A sterile serum vessel used to store and deliver the product EX-CYTE.	A molecular model of a prion protein that causes BSE.

SurModics Pharmaceuticals cGMP Manufacturing and Development Facility,
The new facility in Birmingham, Alabama will increase the productivity of SurModics Pharamceuticals.	The production space includes a 16,000ft² clean space divided into four separate suites.	SurModics' new home will help to develop drug coatings required for sustained release.
Half-suit isolators allow the pharmaceutical coatings to be produced in terminal sterilisation.

University of Maryland Biopark,
The BioPark is a large development in an affluent area of Baltimore.	The BioPark houses start-ups and established companies involved in R&D and also manufacturing of biopharmaceuticals.	The new Baltimore Forensic Center is being constructed as part of the development.
New BioPark buildings may be constructed taller for more floor space.	The Bio-innovation centre has a wide range of wet and dry lab space.	The Genome Centre will also provide facilities for cutting-edge research.
Paragon Bioservices is one tenant that undertakes bio manufacturing in the BioPark.	There will eventually be twelve BioPark buildings but so far two have been completed.

VaxGen Biopharmaceutical Manufacturing Plant,
VaxGen's plant has 17,000ft² of floor space for the manufacture of protein therapeutics, vaccines and monoclonal antibodies, using recombinant bacterial fermentation and mammalian cell cultures.	Schematic of HIV virus. The plant was initially used to manufacture VaxGen's AIDS and anthrax vaccine candidates.	An HIV virus budding from a human cell.
1,000l large bioreactor for manufacturing biopharmaceuticals under cGMP.	Solutions preparation suite.	Water steam generator.

Velesco Pharmaceutical Manufacturing Facility,
The new 10,000ft² Velesco facility in Michigan is devoted to the manufacture of non-sterile cGMP clinical trial supplies.	The GMP laboratory at the Velesco facility will be ready for use by October 2009.	The Velesco facility will use over-encapusalation technology for manufacturing larger tablets.

Wyckoff Active Pharmaceutical Ingredient Plant
The aim of the project was to expand the company’s production capacity by adding a second production plant to the site.	Wyckoff is seeking to expand cGMP (current Good Manufacturing Practice) capabilities.	Wyckoff is a small chemical and pharmaceutical company that was acquired by Catalytica Pharmaceuticals in 1999.
The contractors decided to model the complete plant in 3D and use the 3D model to resolve spacing issues while in the process of designing the new facility.	The piping models and drawings of the project were developed using the software AutoPLANT Piping and AutoPLANT Equipment.	The fitting, piping and valve dimensional/ material data were entered directly into the project database using the AutoPLANT SpecGen (Specification Generator) software.
South Haven, Michigan, USA

Browse Projects